secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001193125-23-019738
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inovio cuts 11% of workforce, expects $4.3M annual savings; securities class action settled for $44M
--------------------------------------------------------------------------------

- Reduced headcount by 24 employees (11% of full-time staff); one-time charge of $1.1M in Q1 2023.
- Expected annual savings of ~$4.3M from reorganization and prior program discontinuations.
- Court granted final approval of $44M securities class action settlement: $30M cash (paid by insurers) plus $14M in stock (initially 7M shares; <5% of outstanding).
- Key data readouts expected Q1 2023 for INO-3107 (RRP) and VGX-3100 (cervical HSIL) trials.
- Restructuring redirects resources to lead DNA medicine candidates; 2022 Q4 results planned for March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/0001193125-23-019738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523019738/d295438d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-019738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer